FERNANDO
PÉREZ RUIZ
Universidad Complutense de Madrid
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Universidad Complutense de Madrid (1)
2017
-
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study
Annals of the Rheumatic Diseases, Vol. 76, Núm. 10, pp. 1679-1687